Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Sep 14, 2015 10:58am
174 Views
Post# 24101430

RE:RE:Highlights from Resverlogix Rodman and Renshaw 9/10

RE:RE:Highlights from Resverlogix Rodman and Renshaw 9/10G1945V,

I don't have enough information to form an opinion on the 3-point vs. 5-point MACE. On Thursday, Don said the the 3-point MACE would be comprised of death, non-fatal MI, and ischemic stroke. I don't know for sure waht the 5-point MACE included. In the ESC 2014 presentation, I see that the table lists death, myocardial infarction, coronary revascularization and "hospitalization for unstable angina or heart failure." I am assuming that these 2014 ESC presentation categories are what the post-hoc analysis for ASSURE/SUSTAIN are based on. If true, then I don't know why ischemic stroke wasn't listed. Perhaps no one in ASSURE/SUSTAIN had ischemic stroke during those 6-month studies. And I am not going to conjecture anything about the FDA. All I can say is that the obvious effect of focusing on 3-point serious MACE events and not also include more moderate MACE events woudl be expected to lower the overal incidence rate. "Is it wise?" you ask. I dunno. "Serious effects on the stats" I dunno. Like I said, I don't have enough information to form an opinion. 

Bear
Bullboard Posts